Glucocorticoid and Sex Hormone Receptors: Clinical Implications and Therapeutic Relevance

Dermatologic Clinics

Volumn 25, Issue 4, 2007, Pages 503-513

  Stefanaki, Christina ^a   Chrousos, George P ^a   Katsambas, Andreas ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 (4 HYDROXYBUTYL) 4,4 DIMETHYL 2,5 DIOXO 1 IMIDAZOLIDINYL] 2 TRIFLUOROMETHYLBENZONITRILE; ANDROGEN; ANTIANDROGEN; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CLOBETASOL PROPIONATE; ESTROGEN; ESTROGEN RECEPTOR; FLUTICASONE; GENISTEIN; GLUCOCORTICOID; LASOFOXIFENE; PHYTOESTROGEN; PREDNISOLONE; RALOXIFENE; RU 58 841; SEX HORMONE; TAMOXIFEN; UNCLASSIFIED DRUG;

DRUG MECHANISM; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN INFLAMMATION; WOUND HEALING;

ANIMALS; DERMATOLOGIC AGENTS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; RECEPTORS, GLUCOCORTICOID; SIGNAL TRANSDUCTION; SKIN DISEASES; SKIN PHYSIOLOGY;

EID: 34648846030     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2007.06.011     Document Type: Review

References (115)

1. Thiboutot D., Jabara S., McAllister J.M., et al. Human skin is a steroidogenic tissue: steroidogenic enzymes and cofactors are expressed in epidermis, normal sebocytes, and an immortalized sebocyte cell line (SEB-1). J Invest Dermatol 120 (2003) 905-914
2. Chen W., Thiboutot D., and Zouboulis C. Cutaneous androgen metabolism: basic research and clinical perspectives. J Invest Dermatol 119 (2002) 992-1007
3. Reichardt H.M., Tronche F., Berger S., et al. New insights into glucocorticoid and mineralocorticoid signaling: lessons from gene targeting. Adv Pharmacol 47 (2000) 1-21
4. De Bosscher K., Berghe W.V., and Haegeman G. The interplay between the glycocorticoid reseptor and nuclear factor-kB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev 24 (2003) 488-522
5. Reichardt H.M., and Schutz G. GC-signaling: multiple variations of a common theme. Mol Cell Endocrinol 146 (1998) 1-6
6. Lifton R.P., Ghavari A.G., and Geller D.S. Molecular mechanisms of human hypertension. Cell 104 (2001) 545-556
7. Shafer-Korting M., Kleuser B., Ahmed M., et al. Glucocorticoids for human skin: new aspects of the mechanism of action. Skin Pharmacol Physiol 18 (2005) 103-114
8. Necela B.M., and Cidlowski J.A. Crystallization of the human glucocorticoid receptor ligand binding domain: a step towards selective glucocorticoids. Trends Pharmacol Sci 24 (2003) 58-61
9. Chrousos G.P., and Kino T. Intracellular glycocorticoid signaling: a formerly simple system turns stochastic. Science 304 (2005) 48-53
10. Kino T., De Martino M.U., Charmandari E., et al. Tissue glucocorticoid resistance/hypersensitivity syndromes. J Steroid Biochem Mol Biol 85 (2003) 457-467
11. Paul-Clark M.J., Roviezzo F., Flower R.J., et al. Glucocorticoid receptor nitration leads to enhanced anti-inflammatory effects of novel steroid ligands. J Immunol 171 (2003) 3245-3252
12. Schacke H., Docke W.D., and Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 96 (2002) 23-43
13. Barnes P.J. Molecular mechanisms of corticosteroids in allergic diseases. Allergy 56 (2001) 928-936
14. Galon J., Franchimont D., Hiroi N., et al. Gene profling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J 16 (2002) 61-71
15. Radoja N., Komine M., Jho S.H., et al. Novel mechanism of steroid action in skin through glucocorticoid receptor monomers. Mol Cell Biol 20 (2000) 4328-4339
16. Winterfield L., Cather J., Cather J., et al. Changing paradigms in dermatology: nuclear hormone receptors. Clin Dermatol 21 (2003) 447-454
17. Perez P., Page A., Brano A., et al. Altered skin development and impaired proliferative and inflammatory responses in transgenic mice overexpressing the glucocorticoid receptor. FASEB J 15 (2001) 2030-2032
18. Oikarinen A., Haapasaari K.M., Sutinen M., et al. The molecular basis of GC-induced skin atrophy: topical GC apparently decreases both collagen synthesis and corresponding collagen m-RNA level in human skin in vivo. Br J Dermatol 139 (1998) 1106-1110
19. Kellendonk C., Tronche F., Reichardt H., et al. Mutagenesis of the glucocorticoid receptor in mice. J Steroid Biochem Mol Biol 69 (1999) 253-259
20. Belvisi M.G., Brown T.G., Wicks S., et al. New glucocorticoids with an improved therapeutic ratio?. Pulm Pharmacol Ther 14 (2001) 221-227
21. Belvisi M.G., Wicks S., Battram C.H., et al. Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity. J Immunol 166 (2001) 1975-1982
22. Coghlan M.J., Kym P.R., Elmore S.W., et al. Synthesis and characterization of non-steroidal ligands for the glucocorticoid receptor: selective quinoline derivatives with prednisolone equivalent functional activity. J Med Chem 44 (2001) 2879-2885
23. Schacke H., Schottelius A., Docke W.D., et al. Dissociation of trnasactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci USA 101 (2004) 227-232
24. Wel C., Nakane M., Stashko M., et al. Trans-activation and repression properties of the novel nonsteroid glucocorticoid receptor ligand 2,5-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5-(1-methylcycloxen-3-y 1)-1H-[1]benzopyrano[3,4-F]quinoline (A276575) and its four stereoisomers. Mol Pharmacol 62 (2002) 297-303
25. Heck S., Kullman M., Gast A., et al. A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1. EMBO J 13 (1994) 4087-4095
26. Liden J., Delauney F., Rafter I., et al. A new function for the C-terminal zinc finger of the glucocorticoid receptor. Repression of RelA transactivation. J Biol Chem 272 (1997) 21467-21472
27. Hofmann T.G., Hehner S.P., Bacher S., et al. Various glucocorticoids differ in their ability to induce gene expression, apoptosis and to repress NF-kB-dependent transcription. FEBS Lett 441 (1998) 441-446
28. Breslin M.B., Geng C.D., and Vedeckis W.V. Multiple promoters exist in the human GR gene, one of which is activated by glucocorticoids. Mol Endocrinol 15 (2001) 1381-1395
29. Bamberger C.M., Bamberger A.M., De Castro M., et al. Glucocorticoid receptor β a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Invest 95 (1995) 2435-2441
30. Lu N.Z., and Cidlowski J.A. Translational regulatory mechanisms generate N-terminal glucocorticoid receptor isoforms with unique transcriptional target genes. Mol Cell 18 (2005) 331-342
31. Kino T., and Chrousos G.P. Glucocorticoid and mineralocorticoid receptors and associated diseases. Essays Biochem 40 (2004) 137-155
32. Charmandari E., Chrousos G.P., Ichijo T., et al. The human glucocorticoid receptor (hGR) β isoform suppresses the transcriptional activity of hGRa by interfering with formation of active coactivator complexes. Mol Endocrinol 19 (2005) 52-64
33. Yudt M.R., Jewell C.M., Bienstock R.J., et al. Molecular origins for the dominant negative function of human glucocorticoid receptor β. Mol Cell Biol 23 (2003) 4319-4330
34. Spica I., Hammer S., Kleuser B., et al. Transcriptional activity of potent glucocorticoids: relevance of glucocorticoid receptor isoforms and drug metabolites. Skin Pharmacol Appl Skin Physiol 16 (2003) 143-150
35. Hamid Q.A., Wenzel S.E., Hauk P.J., et al. Increased glucocorticoid receptor beta in airway cells of glucocorticoid-insensitive asthma. Am J Respir Crit Care Med 159 (1999) 1600-1604
36. Leung D.Y., Hamid Q., Vottero A., et al. Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor beta. J Exp Med 186 (1997) 1567-74
37. Sousa A.R., Lane S.J., Cidlowski J.A., et al. Glucocorticoid resistance in asthma is associated with elevated in vivo expression of the glucocorticoid receptor beta-isoform. J Allergy Clin Immunol 105 (2000) 943-950
38. Kino T., Tulpakov A., Ichijo T., et al. G protein β interacts with the glucocorticoid receptor and suppresses its transcriptional activity in the nucleus. J Cell Biol 169 (2005) 885-896
39. Belgi G., and Friedman P.S. Traditional therapies: glucocorticoids, azathioprine, methotrexate, hydroxyurea. Clin Exp Dermatol 27 (2002) 546-554
40. Croxtal J.D., Van Hal P.T., Choudhury Q., et al. Different glucocorticoids vary in their genomic and non-genomic mechanism of action in A549 cells. Br J Pharmacol 135 (2002) 511-519
41. Barnes P.J., and Adcock I.M. How do corticosteroids work in asthma?. Ann Intern Med 139 (2003) 359-370
42. Korting H.C., Unholzer A., Schaffer-Korting M., et al. Different skin thinning potential of equipotent medium-strength glucocorticoids. Skin Pharmacol Appl Skin Physiol 15 (2002) 85-91
43. Hanafin J., Abrams B., and Cherill R. Management of atopic dermatitis with prednicarbate emollient cream 0.1%, a nonhalogenated prednisolone derivative. Journal of Geriatric Dermatology 2 (1994) 119-127
44. Schaffer-Korting M., Korting H.C., Kerscher M.J., et al. Prednicarbate activity and benefit/risk ratio in relation to other topical glucocorticoids. Clin Pharmacol Ther 54 (1993) 448-456
45. Kariya Y., Moriya T., Suzuki T., et al. Sex steroid hormone receptors in human skin appendages and its neoplasms. Endocr J 52 (2005) 317-325
46. Fritsch M., Orfanos C.E., and Zouboulis C.C. Sebocytes are the key regulators of androgen homeostasis in human skin. J Invest Dermatol 116 (2001) 793-800
47. Hoffman R. Steroidogenic isoenzymes in human hair and their potential role in androgenetic alopecia. Dermatology 206 (2003) 85-89
48. Rabe T., Grunwald K., and Runnebaum B. Hyperandrogenism in women. In: Runnebaum B., and Rabe T. (Eds). Gynecological endrocrinology and reproductive medicine. Vol 1 (1994), Springer-Verlag, Berlin (Heidelberg) 591-592
49. Lubahn D.B., Joseph D.R., Sullivan P.M., et al. Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science 240 (1988) 327-330
50. Lee H.J., and Chang C. Recent advances in adrogen receptor action. Cell Mol Life Sci 60 (2003) 1613-1622
51. Hellwinkel O.J.C., Muller A., Struve D., et al. Influence of androgens and age on androgen receptor and 5a-reductase II transcription. Eur J Endocrinol 143 (2000) 217-225
52. Quigley C.A., De Bellis A., Marshke K.B., et al. Androgen receptor defects: historical, clinical and molecular perspectives. Endocr Rev 16 (1995) 271-321
53. Beato M., Chavez S., and Truss M. Transcriptional regulation by steroid hormones. Steroids 61 (1996) 240-251
54. Roche P.J., Hoare S.A., and Parker M.G. A consensus DNA-binding sit for the androgen receptor. Mol Endocrinol 6 (1992) 2229-2235
55. Claessens F., Verrijidt G., Schoenmakers E., et al. Selective DNA binding by the androgen receptor as a mechanism for hormone specific gene regulation. J Steroid Biochem Mol Biol 76 (2001) 23-30
56. Heinlein C.A., and Chang C. Androgen receptor coregualtors: an overview. Endocr Rev 23 (2002) 175-200
57. Chang C., Saltzman A., Yeh S., et al. Androgen receptor: an overview. Crit Rev Eukaryot Gene Expr 5 (1995) 97-125
58. Azziz R., Carmina E., and Sawaya M.E. Idiopathic hirsutism. Endocr Rev 21 (2000) 347-362
59. Tilley W.D., Marcelli M., and McPhaul M.J. Recent studies on the androgen receptor: new insights into old questions. Mol Cell Endocrinol 68 (1990) C7-C10
60. Edwards A., Hammond H.A., Jin L., et al. Genetic variations at five tetrameric tandem repeat loci in four human population groups. Genomics 12 (1992) 241-253
61. Sawaya M.E., and Shalita A.R. Androgen receptor polymorphisms (GAG repeat lengths) in androgenetic alopecia, hirsutism and acne. J Cutan Med Surg 3 (1998) 9-15
62. Legro R.S., Shahbahrami B., Lobo R.A., et al. Size polymorphisms of the androgen receptor among female Hispanics and correlations with androgenic characteristics. Obstet Gynecol 83 (1994) 701-706
63. Choudry R., Hodgins M.B., Van der Kwast T.H., et al. Localization of androgen receptors in human skin by immunohistochemistry: implications for the hormonal regulation of hair growth, sebaceous glands and sweat glands. J Endocrinol 133 (1992) 467-475
64. Deplewski D., and Rosenfield R.L. Role of hormones in pilosebaceous unit development. Endocr Rev 21 (2000) 363-392
65. Inui S., Fukuzato Y., Nakajima T., et al. Androgen-inducible TGF-b1 from balding dermal papilla cells exhibits epithelial cell growth: a clue to understanding paradoxical effects of androgen on human hair growth. FASEB J 16 (2002) 1967-1969
66. Raudrant D., and Rabe T. Progesterones with antiandrogenic properties. Drugs 63 (2003) 463-492
67. Diamanti-Kandarakis E. Current aspects of antiandrogen therapy in women. Curr Pharm Des 5 (1999) 707-723
68. Battmann T., Bonfils A., Branche C., et al. RU 58841 a new specific topical antiandrogen: a candidate of choice for the treatment of acne, androgenetic alopecia and hirsutism. J Steroid Biochem Mol Biol 48 (1994) 55-60
69. De Brouwer B., Tetelin C., Leroy T., et al. A controlled study of the effects of RU 58841, a non-steroidal antiandrogen, on human hair production by balding scalp grafts maintained on testosterone-conditioned nude mice. Br J Dermatol 137 (1997) 699-702
70. Pan H.J., Wilding G., Uno H., et al. Evaluation of RU58841 as an anti-androgen in prostate PC3 cells and a topical anti-alopecia agent in the bald scalp of stumptailed macaques. Endocrine 9 (1998) 39-43
71. Munster U., Nakamura C., Haberland A., et al. RU 58841-myristate-prodrug development for topical treatment of acne and androgenetic alopecia. Pharmazie 60 (2005) 8-12
72. Ashcroft G.S., and Mills S.J. Androgen receptor-mediated inhibition of cutaneous wound healing. J Clin Invest 110 (2002) 615-624
73. Nelson L.R., and Bulun S.E. Estrogen production and action. J Am Acad Dermatol 45 Suppl (2001) S116-S124
74. Hall G., and Phillips T.J. Estrogen and skin: the effects of estrogen, menopause, and hormone replacement therapy on the skin. J Am Acad Dermatol 53 (2005) 555-568
75. Nilson S., Makela S., Treuter E., et al. Mechanisms of estrogen action. Physiol Rev 81 (2001) 1535-1565
76. Shearman A.M., Cupples L.A., Demissie S., et al. Association between estrogen receptor alpha gene variation and cardiovascular disease. JAMA 290 (2003) 2263-2270
77. Herrington D.M., Vittinghoff E., Lin F., et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation 105 (2002) 917-922
78. Tungeon J.L., McDonnel D.P., Martin K.A., et al. Hormone therapy: physiological complexity belies therapeutic simplicity. Science 304 (2004) 1269-1273
79. Nardulli A.M., and Shapiro D.J. DNA binding by nuclear receptors. Receptor 3 (1993) 247-255
80. Weisz A., and Rosales R. Identification of an estrogen response element upstream of the human c-fos gene that binds estrogen receptor and the AP-1 transcription factor. Nucleic Acids Res 18 (1990) 5097-6106
81. Losel R.M., Falkenstein E., Feuring M., et al. Nongenomic steroid action: controversies, questions, and answers. Physiol Rev 83 (2003) 965-1016
82. Kamat A., Hinshelwood M.M., Murry B.A., et al. Mechanisms in tissue-specific regulation of estrogen biosynthesis in humans. Trends Endocrinol Metab 13 (2002) 122-128
83. Klotz D.M., Hewitt S.C., Ciana P., et al. Requirements of estrogen receptor alpha in insulin like growth factor-1 (IGF-1) induced uterine responses and in vivo evidence for IGF-1/estrogen receptor cross talk. J Biol Chem 277 (2002) 8531-8537
84. Filardo E.J. Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30; a novel signaling pathway with potential significance for breast cancer. J Steroid Biochem Mol Biol 80 (2002) 231-238
85. Peach K., Webb P., Kuiper G.G., et al. Differential ligand activation of estrogen receptors ER-a and ER-β at AP-1 sites. Science 277 (1997) 1508-1510
86. Ohnemus U., Uenalan M., Conrad F., et al. Hair cycle control by estrogens: catagen induction via estrogen receptor (ER)-a is checked by ER-b signaling. Endocrinology 146 (2005) 1214-1225
87. Petterson K., Delaunay F., and Gustafson J.A. Estrogen receptor β acts as a dominant regulator of estrogen signaling. Oncogene 19 (2000) 4970-4978
88. Saji S., Omoto Y., Shimizu C., et al. Expression of estrogen receptor (ER) β cx protein in ER-a positive breast cancer: specific correlation with progesterone receptor. Cancer Res 62 (2002) 4849-4853
89. Weihua Z., Ekman J., Almkvist A., et al. Involvement of androgen receptor in 17β estradiol induced proliferation in rat uterus. Biol Reprod 67 (2002) 616-623
90. Ettinger B., Black D.M., Mitlak B.H., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifen: results from a 3-year randomized clinical trial. Multiple outcomes of Raloxifen Evaluation (MORE) Investigators. JAMA 282 (1999) 637-645
91. Ke H.Z., Foley H.A., Simmons V., et al. Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats. Endocrinology 145 (2004) 1996-2005
92. Labrie F., El-Alfy M., Berger L., et al. The combination of a novel selective estrogen receptor modulator with an estrogen protects the mammary gland and uterus in a rodent model: the future of postmenopausal women's health?. Endocrinology 144 (2003) 4700-4706
93. Gustafson J.A. Therapeutic potential of selective estrogen receptor modulators. Curr Opin Chem Biol 2 (1998) 508-511
94. Fitzpatrick L.A. Selective estrogen receptor modulators and phytoestrogens: new therapies for the postmenopausal woman. Mayo Clin Proc 74 (1999) 601-607
95. Beck V., Unterrieder E., Krenn L., et al. Comparison of standardized plant extracts for large scale use in hormone therapy. J Steroid Biochem Mol Biol 84 (2003) 259-268
96. Schmid D., Muggli R., and Zulli E. Dermatological application of soy isoflavones to skin ageing in post menopausal women. Cosmetics and Toiletries 1 (2001) 146-151
97. Schmid D., and Zulli E. Topically applied soy isoflavones increase skin thickness. Cosmetics and Toiletries 117 (2002) 45-50
98. Kanda N., and Watanabe S. 17-β estradiol inhibits oxidative stress-induced apoptosis in keratinocytes by promoting bcl-2 expression. J Invest Dermatol 121 (2003) 1500-1509
99. Kim S.Y., Kim S.J., Lee J.Y., et al. Protective effects of dietary soy isoflavones against UV induced skin aging in the hairless mouse. J Am Coll Nutr 23 (2004) 157-162
100. Kang S., Chung J.H., Lee J.H., et al. Topical N-acetyl cysteine and genistein prevents ultraviolet-light-induced signaling that leads to photo-aging in human skin in vivo. J Invest Dermatol 120 (2003) 835-841
101. Wei H., Saladi R., Lu Y., et al. Isoflavone genistein: phytoprotection and clinical implications in dermatology. J Nutr 133 Suppl (2003) 3811-3819
102. Pelletier G., and Ren L. Localization of sex steroid receptors in human skin. Histol Histopathol 19 (2004) 629-636
103. Thorton M.J., Taylor A.H., and Mulligan K. Oestrogen receptor beta is the predominant estrogen receptor in human scalp skin. Exp Dermatol 12 (2003) 181-190
104. Pelletier G., Labric C., and Labrio F. Localization of oestrogen receptor a, oestrogen receptor b and androgen receptors in the rat reproductive organs. J Endocrinol 165 (2000) 359-370
105. Callens A., Vaillant L., Lecompte P., et al. Does hormonal aging exist? A study of the influence of different hormone therapy regimens on the skin of postmenopausal women using non-invasive measurement techniques. Dermatology 193 (1996) 289-294
106. Verdier-Sevrain S., Yaar M., Cantatore J., et al. Estradiol induces proliferation of keratinocytes via receptor-mediated mechanisms. FASEB J 18 (2004) 1252-1254
107. Moverare S., Lindberg M.K., Faegerman J., et al. Estrogen receptor a, but not b, is involved in the regulation of the hair follicle cycling as well as the thickness of epidermis in male mice. J Invest Dermatol 119 (2002) 1053-1058
108. Surazynski A., Jarzabek K., Haczynski J., et al. Differential effects of estradiol and raloxifene on collagen biosythesis in cultured human skin fibroblasts. Int J Mol Med 12 (2003) 803-809
109. Kahlert S., Nuedling S., Van Eickels M., et al. Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. J Biol Chem 275 (2000) 18447-18453
110. Ashcroft G.S., Greenwell-Wild T., Horan M.A., et al. Topical estrogen accelerates cutaneous wound healing in aged humans associated with an altered inflammatory response. Am J Pathol 155 (1999) 1137-1146
111. Son E.D., Lee J.Y., Lee S., et al. Topical application of 17b-estradiol increases extracellular matrix protein synthesis by stimulating TGF-b signaling in aged human skin in vivo. J Invest Dermatol 124 (2005) 1149-1161
112. Conrad F., Ohnemus U., Gerstmayer B., et al. Estrogens and human hair scalp hair growth-still more questions than answers. J Invest Dermatol 122 (2004) 840-842
113. Conrad F., Ohnemus U., Bodo E., et al. Substantial sex-dependent differences in the response of human scalp hair follicles to estrogen stimulation in vitro advocate gender-tailored management of female versus male pattern balding. Journal of Investigative Dermatology Symposium Proceedings 10 3 (2005) 243-246
114. Oh H.S., and Smart R.C. An estrogen receptor pathway regulates the telogen-anagen hair follicle transition and influences epidermal cell proliferation. Proc Natl Acad USA 93 (1996) 12525-12530
115. Wallace N.B., and Smaller B.R. Estrogen and progesterone receptors in androgenetic alopecia versus alopecia areata. American Journal of Dermatology 2 (1998) 160-163